Anemia: Clinical Trials

457 trials for Anemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

457 completed. 457 Phase 3, 52 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3457Completed 457
Phase 252Completed 52

Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia

Trials (filtered) newest first · largest first

All 457 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.
Erythropoietin + Probiotic, EPO - Anaemia, Chronic Kidney Disease
Phase 3CompletedBadr University802026-02-012026-10-30
Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia
HSK39297 tablets - Paroxysmal Nocturnal Haemoglobinuria (PNH)
Phase 3CompletedHaisco Pharmaceutical Group Co., Ltd.362025-05-122026-02-11
Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2)
zinc sulfate, Placebo - Sickle Cell Disease
Phase 2 / Phase 3CompletedIndiana University1002025-02-102026-01-30
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
HRS-5965 capsule - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedChengdu Suncadia Medicine Co., Ltd.392025-01-072026-01-08
Effectiveness of Oral Iron Therapy in Iron Deficiency Anemia With Daily vs Alternate Day Dosing
Ferrous sulphate - Iron Deficiency Anemia, Iron Deficiency Anemia Treatment
Phase 3CompletedUniversity of Child Health Sciences and Children's Hospital, Lahore602025-01-072026-06-16
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
HRS-5965 capsule, Eculizumab Injection - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedChengdu Suncadia Medicine Co., Ltd.762024-10-252025-09-11
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH
Phase 3CompletedAlexion Pharmaceuticals, Inc.182024-10-102026-06-05
Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman
Low dose IHAT, High Dose IHAT, Carob flour - Iron-deficiency
Phase 3CompletedRDC Clinical Pty Ltd1802024-03-062025-03-10
Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women
Low Dose IHAT, High Dose IHAT, Carob Flour - Iron-deficiency
Phase 3CompletedNemysis Ltd1802024-03-052025-06-04
Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia
Ferric Carboxymaltose (FCM) - Anemia, Anemia, Postpartum
Phase 2 / Phase 3CompletedESI-PGIMSR, Basaidarapur2002024-03-012026-06-15
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
Venofer 200 MG Per 10 ML Injection, Ferrous sulfate - Iron Deficiency Anemia of Pregnancy
Phase 3CompletedArrowhead Regional Medical Center5182023-11-212026-11-09
Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis
SAL-0951 tablets, rHuEPO injection - Anemia
Phase 3CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.1002023-09-192024-12-06
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Daprodustat - Anaemia
Phase 3CompletedGlaxoSmithKline42023-09-062025-11-10
Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia
L-glutamine - Pulmonary Artery Pressure, Thalassemia
Phase 2 / Phase 3CompletedMazandaran University of Medical Sciences82023-08-152025-10-07
Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias
Tranexamic Acid (TXA) treatment, Placebo - Anemia, Small Bowel Bleeding
Phase 2 / Phase 3CompletedLouisiana State University Health Sciences Center in New Orleans402023-08-012025-08-15
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Eculizumab - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedAlexion Pharmaceuticals, Inc.252023-07-052026-06-01
Prevention of Iron Deficiency Anemia Post-delivery
Ferric carboxymaltose (FCM) and folic acid tablets, Oral iron tablets and folic acid tablets - Postpartum Anemia
Phase 3CompletedNICHD Global Network for Women's and Children's Health48572023-05-302026-07-01
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis
Phase 2 / Phase 3CompletedCure HHT712023-05-082026-10-27
Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
Iptacopan - Paroxysmal Nocturnal Hemoglobinuria
Phase 3CompletedNovartis Pharmaceuticals522023-04-242026-01-13
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Pegcetacoplan, Placebo matching Pegcetacoplan - Cold Agglutinin Disease
Phase 3CompletedSwedish Orphan Biovitrum242022-10-202025-10-30

Showing 20 of 457. Sign in to see all of them.

Narrower conditions

Renal Insufficiency, Chronic (64)  ·  Anemia, Iron-Deficiency (61)  ·  Anemia, Sickle Cell (44)  ·  Hemoglobinuria, Paroxysmal (30)  ·  Myelodysplastic Syndromes (27)  ·  Anemia, Refractory, with Excess of Blasts (23)  ·  Iron Deficiencies (20)  ·  Leukemia (20)  ·  beta-Thalassemia (16)  ·  Kidney Failure, Chronic (15)  ·  Neoplasms (15)  ·  Renal Insufficiency (15)  ·  Hematologic Diseases (14)  ·  Leukemia, Myeloid, Acute (14)

Broader conditions

Hemic and Lymphatic Diseases (457)  ·  Hematologic Diseases (443)  ·  Pathological Conditions, Signs and Symptoms (130)  ·  Pathologic Processes (120)  ·  Anemia, Hemolytic (111)  ·  Disease Attributes (96)  ·  Urogenital Diseases (92)  ·  Female Urogenital Diseases and Pregnancy Complications (90)  ·  Chronic Disease (89)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (89)  ·  Female Urogenital Diseases (86)  ·  Male Urogenital Diseases (85)  ·  Nutritional and Metabolic Diseases (85)  ·  Metabolic Diseases (84)

Interventions

Darbepoetin alfa (51)  ·  Epoetin Alfa (48)  ·  ferric carboxymaltose (36)  ·  continuous erythropoietin receptor activator (34)  ·  Iron (23)  ·  ferrous sulfate (21)  ·  eculizumab (19)  ·  Ferric Oxide, Saccharated (17)  ·  Iron-Dextran Complex (14)  ·  Cyclophosphamide (13)  ·  Hydroxyurea (13)  ·  roxadustat (13)  ·  Erythropoietin (11)  ·  epoetin beta (10)  ·  fludarabine phosphate (10)

Sponsors

Hoffmann-La Roche (36)  ·  Amgen (24)  ·  American Regent, Inc. (20)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (17)  ·  Pharmacosmos A/S (13)  ·  Alexion Pharmaceuticals, Inc. (12)  ·  GlaxoSmithKline (10)  ·  Novartis Pharmaceuticals (9)  ·  AMAG Pharmaceuticals, Inc. (8)  ·  Assistance Publique - Hôpitaux de Paris (8)  ·  London School of Hygiene and Tropical Medicine (8)  ·  National Heart, Lung, and Blood Institute (NHLBI) (8)  ·  Akebia Therapeutics (6)  ·  Kyntra Bio (6)  ·  Bayer (5)

Countries

United States (178)  ·  France (78)  ·  Italy (72)  ·  United Kingdom (70)  ·  Germany (68)  ·  Canada (62)  ·  Spain (62)  ·  Australia (44)  ·  Poland (42)  ·  Japan (39)  ·  Russia (38)  ·  Belgium (37)  ·  Brazil (33)  ·  Netherlands (33)  ·  South Korea (33)

Top investigators

Vice President, Clinical Development (4)  ·  Michael R. DeBaun, MD, MPH (3)  ·  Steven Fishbane, MD (3)  ·  Ahmed F Mahmoud Hussein, MS.c (2)

Results publications

PMID 36005278, PMID 36791280, PMID 26965694, PMID 23343061, PMID 23343062, PMID 34932836, PMID 36749544, PMID 37975597, PMID 38363466, PMID 40359056, PMID 41114449, PMID 31203241, PMID 34362786, PMID 16710026, PMID 17634466, PMID 17666600, PMID 18227526, PMID 19721013, PMID 19920054, PMID 22874106, PMID 25545376, PMID 27237709, PMID 30952488, PMID 31203242, PMID 31974203, PMID 32016310, PMID 33283989, PMID 33783815, PMID 33913637, PMID 33913638, PMID 34175041, PMID 34526067, PMID 36565721, PMID 36594181, PMID 37095342, PMID 37096396, PMID 37651553, PMID 38383961, PMID 38477987, PMID 38530490, PMID 38727860, PMID 38775255, PMID 39079163, PMID 39231617, PMID 40447351, PMID 40576086, PMID 40694294, PMID 40720060, PMID 11581447, PMID 15520109

NIH funding

2016 (10), 2017 (7), 2005 (3), 2008 (3), 2014 (3), 2015 (3), 2019 (3), U10CA021115 (3), 1RC2HL101458-01 (1), 2004 (1), 2009 (1), 2023 (1), K12HD103084 (1), K23HL132001 (1), K23HL136787 (1)